Clinicians recommend starting abemaciclib at 100mg BID, rather than the standard 150mg, to mitigate initial GI toxicity. This dose-escalation approach, supported by the TRADE study, improves long-term adherence and allows more patients to reach the target dose without discontinuing.
A retrospective analysis of the MA27 trial suggests patients with invasive lobular cancer have worse outcomes with exemestane. This is attributed to an androgenic metabolite, prompting experts to prefer anastrozole or letrozole for this specific histological subtype.
For patients with 1-3 positive nodes and low-risk biology (e.g., low-grade lobular, low recurrence score), experts are comfortable deferring chemotherapy. This challenges traditional node-based risk assessment, prioritizing tumor biology to avoid unnecessary toxicity in otherwise high-risk patients.
Patients are often exhausted after primary treatment and surprised by the recommendation for two additional years of intensive oral therapy. Clinicians should introduce this possibility early in the treatment journey to manage expectations and prevent the patient from feeling overwhelmed later on.
The SERENA-6 strategy of switching to an oral SERD upon detecting an ESR1 mutation in ctDNA—before clinical progression—is a novel concept. It forces oncologists to grapple with the idea of 'molecular progression' and whether this biomarker-led switch truly alters the disease's natural history.
Experts found the early and significant separation of survival curves in the adjuvant Ladera trial for giredestrant "stunning." This rapid divergence suggests a powerful biological effect, drawing parallels to the historically impactful introduction of aromatase inhibitors over tamoxifen.
Data from trials like RIGHT Choice demonstrates that a CDK4/6 inhibitor with endocrine therapy is superior to combination chemotherapy, even for patients with aggressive features like symptomatic visceral metastases. This provides compelling evidence to avoid initial chemotherapy in this population.
Clinicians should not halt abemaciclib for a mild rise in creatinine, as it's often a spurious lab finding due to altered tubular secretion, not renal injury. Ordering a cystatin C test can confirm normal kidney function, allowing patients to safely continue treatment.
An Emory University study using a medication-tracking app found that anxiety and depression were significantly associated with lower adherence to oral CDK4/6 inhibitors. This provides data-driven evidence for the critical need to proactively screen for and manage mental health to ensure treatment efficacy.
The VICTORIA-1 trial showed an unprecedented benefit for the gedatolisib triplet, with a hazard ratio of 0.24 in PIK3CA wild-type patients. The dramatic improvement suggests that PAM pathway activation is a dominant resistance mechanism even without a PIK3CA mutation, opening a new treatment avenue.
Based on Germany's ADAPT trial, a 3-week course of pre-operative endocrine therapy can serve as a dynamic biomarker. If the Ki-67 proliferation marker drops below 10%, select patients with positive nodes can safely omit adjuvant chemotherapy, with excellent 5-year outcomes.